mahesh parmar is professor of epidemiology at university college london — he's been leading clinicalthank you very much for joining us. it's an international trial, then. tell us a little bit about it. this trial recruited just over 1000 patients in 68 hospitals in the us, southeast asia, many countries in europe including the uk, greece, denmark, spain and germany. and the trial of those more than 100,000 participants, half were given remdesivir and half were given placebo. the time to recovery for those given remdesivir, it was 11 days compared to 15 days for the patient‘s who received a placebo. how encouraging are these preliminary results, then? everyone's looking for that silver bullet. they are, of course, and these results are very encouraging. you have to remember the last patient entered this trial on april the 19th, and we are just two weeks from that now, so the data are very early. having said that, the data on time to recovery are very, very clear. we have to wait for the death data to come through. they will emerge over the next month or so. the initial data are very e